Ameriprise Financial Inc Vbi Vaccines Inc Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.64 $4,154 - $9,168	-14,325 Reduced 51.46%	13,510 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.38 - $22.5 $7,168 - $424,462	-18,865 Reduced 40.4%	27,835 $10,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $23.4 $7,008 - $224,640	-9,600 Reduced 17.05%	46,700 $33,000
Q2 2022 Aug 15, 2022	BUY	$0.66 - $1.81 $4,596 - $12,606	6,965 Added 14.12%	56,300 $46,000
Q1 2022 May 16, 2022	BUY	$1.27 - $2.47 $44 - $86	35 Added 0.07%	49,335 $82,000
Q4 2021 Feb 14, 2022	SELL	$2.21 - $3.22 $50,841 - $74,076	-23,005 Reduced 31.82%	49,300 $115,000
Q3 2021 Nov 15, 2021	SELL	$2.8 - $3.72 $2,800 - $3,720	-1,000 Reduced 1.36%	72,305 $225,000
Q2 2021 Aug 16, 2021	SELL	$2.61 - $4.17 $13 - $20	-5 Reduced 0.01%	73,305 $246,000
Q1 2021 May 17, 2021	BUY	$2.91 - $4.32 $149,501 - $221,940	51,375 Added 234.21%	73,310 $228,000
Q4 2020 Feb 12, 2021	BUY	$2.15 - $3.5 $17,898 - $29,137	8,325 Added 61.17%	21,935 $60,000
Q3 2020 Nov 16, 2020	BUY	$2.77 - $6.17 $37,699 - $83,973	13,610 New	13,610 $39,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.